Spackman Equities Group Inc. Engaged to Advise CanariaBio Inc. on TSX Venture Exchange
The common shares of Spackman Equities Group trades on the TSX Venture Exchange under the symbol SQG. Visit www.spackmanequities.com for further information.
14 NEWS16d
Israel identifies remains of child hostages but says body Hamas returned was not their mother
TEL AVIV, Israel (AP) — The Israeli military said Friday it had positively identified the remains of two young hostages but another body released by Hamas under a ceasefire deal was not the boys ...
Us Weekly16d
Princess Anne Family Guide: Meet the Princess Royal’s 2 Kids and 5 Grandchildren
The only daughter of the late Queen Elizabeth II, Princess Anne has played an active role in the British royal family for decades. Even as she gets older, the Princess Royal says she has no ...
Cleveland.com17d
Israel grieves as Hamas turns over the remains said to be of a mother and her 2 young children
JERUSALEM (AP) — Ariel and Kfir Bibas — two of the youngest hostages held in Gaza — became a symbol for Israelis of the brutality of Hamas' Oct. 7, 2023, attack. The return of what are ...
Cure Today18d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
Oncology Nurse Advisor19d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly increases pathological complete response rates. (HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER ...
Cure Today20d
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...
Targeted Oncology21d
The Targeted Pulse: The Latest FDA Actions Across Cancer Types and Exploring the Efficiency of Remote Pharmacists in Community Oncology
Test The FDA has expanded the approval for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to include patients with HR+, HER2-ultralow metastatic breast cancer who may benefit from ...
Oncology Nurse Advisor23d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...
National Institute for Health and Care Excellence25d
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Targeted Oncology1mon
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The FDA has expanded the label for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody. This enables the identification of patients with hormone receptor (HR)-positive, HER2-ultralow ...